Page 8 - TD-1-1

Tumor Discovery Exploring best ways to fight cancer

mechanistic study of CRCI and facilitate the development mortality worldwide for 36 cancers in 185 countries. CA
of detailed diagnostic and therapeutic strategies for such Cancer J Clin, 71: 209–249.
patients . The relationship between PD-1 expression https://doi.org/10.3322/caac.21660
[13]
and prognosis in cancers has been widely reported. Shi
et al. investigated the clinicopathological and prognostic 3. Lee YT, Tan YJ, Oon CE, 2018, Molecular targeted
therapy: Treating cancer with specificity. Eur J Pharmacol,
significance of PD-1 mRNA expression in various cancers 834: 188–196.
based on Kaplan–Meier plotter databases and found that
the mRNA expression of PD-1 was associated with the https://doi.org/10.1016/j.ejphar.2018.07.034
overall survival of gastric cancer, breast cancer, ovarian 4. Ruiz-Cordero R, Devine WP, 2020, Targeted therapy and
cancer and liver cancer (p < 0.05), relapse-free survival of checkpoint immunotherapy in lung cancer. Surg Pathol Clin,
breast cancer, ovarian cancer and liver cancer (p < 0.05), 13(1): 17–33.
post-progression survival of gastric cancer (p < 0.05), and https://doi.org/10.1016/j.path.2019.11.002
progression-free survival and disease-specific survival 5. Zhong L, Li Y, Xiong L, et al., 2021, Small molecules in
of liver cancer . These results corroborate the role targeted cancer therapy: Advances, challenges, and future
[14]
of PD-1 in different cancers and may inspire further perspectives. Signal Transduct Target Ther, 6(1): 201.
investigations that explore PD-1-targeting agents for the
treatment of different cancers. Furthermore, single-cell https://doi.org/10.1038/s41392-021-00572-w
analysis is critical to providing new insights for studying 6. Dhar R, Seethy A, Singh S, et al., 2021, Cancer
human cancer. Given the important role of monocytes in immunotherapy: Recent advances and challenges. J Cancer
tumor microenvironment (TME), Fu and Yin reviewed Res Ther, 17(4): 834–844.
the monocytes in tumor from the perspective of single- https://doi.org/10.4103/jcrt.jcrt_1241_20
cell analysis and summarized the potential of monocytes 7. Taefehshokr S, Parhizkar A, Hayati S, et al., 2022, Cancer
and their derived cells as diagnostic and therapeutic immunotherapy: Challenges and limitations. Pathol Res
targets, as well as the interaction between monocytes and Pract, 229: 153723.
immune checkpoint therapies . The authors proposed
[15]
that monocytes in TME were quite promising targets https://doi.org/10.1016/j.prp.2021.153723
for the diagnosis and treatment of human cancers. In 8. Kraehenbuehl L, Weng CH, Eghbali S, et al., 2022,
addition, a group of physicians reported a case of anti-PD1 Enhancing immunotherapy in cancer by targeting emerging
immunotherapy for patient with advanced pancreatic immunomodulatory pathways. Nat Rev Clin Oncol, 19(1):
cancer . The survival period of this patient with 37–50.
[16]
pancreatic cancer, who was given a combined treatment https://doi.org/10.1038/s41571-021-00552-7
of surgical resection, chemotherapy, molecular targeted 9. Zhang Y, Zhang Z, 2020, The history and advances in
medicine, and anti-PD1 immunotherapy, was more than cancer immunotherapy: Understanding the characteristics
6 years since diagnosis. This observation corroborates the of tumor-infiltrating immune cells and their therapeutic
potential of immunotherapy in combination with other implications. Cell Mol Immunol, 17(8): 807–821.
therapeutic strategies in treating pancreatic cancer.
https://doi.org/10.1038/s41423-020-0488-6
Finally, the editorial team of Tumor Discovery sincerely 10. Torre LA, Bray F, Siegel RL, et al., 2015, Global cancer
welcomes submissions from all prospective authors. All statistics, 2012. CA Cancer J Clin, 65(2): 87–108.
submissions will be professionally handled at peer-review
stage and speedily processed to reach the target audience. https://doi.org/10.3322/caac.21262
11. Majd MH, 2022, Dual-targeting and specific delivery
Conflict of interest of tamoxifen to cancer cells by modified magnetic
The author declares no potential conflicts of interest. nanoparticles using hyaluronic acid and folic acid. Tumor
Discov, 1(1): 41.
References https://doi.org/10.36922/td.v1i1.41
1. Bray F, Laversanne M, Weiderpass E, et al., 2021, The 12. Wefel JS, Kesler SR, Noll KR, et al., 2015, Clinical
ever-increasing importance of cancer as a leading cause of characteristics, pathophysiology, and management of
premature death worldwide. Cancer, 127(16): 3029–3030. noncentral nervous system cancer-related cognitive
impairment in adults. CA Cancer J Clin, 65: 123–138.
https://doi.org/10.1002/cncr.33587
https://doi.org/10.3322/caac.21258
2. Sung H, Ferlay J, Siegel RL, et al., 2021, Global cancer
statistics 2020: GLOBOCAN estimates of incidence and 13. Jiang J, Du Z, Wang Y, et al., 2022, Advances in the study

Volume 1 Issue 1 (2022) 2 https://doi.org/10.36922/td.v1i1.86